FDA Approved: OXBRYTA — Original Application (Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.)

View source ↗

Summary

FDA approved OXBRYTA (voxelotor) under the original application for the treatment of sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

ORIG AP for OXBRYTA (VOXELOTOR)